Shattuck Labs, Inc.
For the period ended Aug 11, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 11, 2026 · Filed Aug 11, 2026
Use the contents to explore the available documents and sections.
STTK$4.62+2.9%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · DR3 Program Development in 2026
DR3 Program Development in 2026
Shattuck is advancing a pipeline of DR3-targeted monoclonal and bispecific antibody product candidates for the treatment of inflammatory and immune-mediated diseases.
Recent updates and anticipated upcoming milestones include:
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.